Table 1.
Overview of all the diseases mentioned and their N-linked glycan specifications.
| Frequency | Distribution | Glycan type | Proposed function | |
|---|---|---|---|---|
| HD | 15–20% (13) | CDR3 | Complex (bisecting GlcNAc, sialylated) (14, 15) |
|
| RA ACPA | >90% (13) | FR3 (16) | Complex (highly sialylated, bisecting GlcNAc, core fucose) (13) |
Creates possible optimal balance |
| ANCA MPO | Unknown | FR3 (17) | Complex (galactosylated and mono-or di-sialylated) (18) |
Impact functional and structural characteristics of the immunoglobulin |
| SLE | Unknown | Unknown | Unknown | |
| pSS anti-SS-A and/or anti-SS-B | ~23% (19, 20) | FR3 (20) | Complex (20) (Sialylated) | Selection advantage |
| MG anti-MuSK | Unknown | Unknown | Unknown | |
| IgG4-RD | Unknown | Unknown | Complex (Sialylated) (21) |
Unique effector function, interaction with Siglecs |
| FL | 79–100% (22) | CDR2 (22, 23) | Mannose | Selection advantage |
| PCFCL | Unknown | CDR2 (24) | Unknown | |
| DCBCL | 41% (22) | CDR3 (25) | Unknown | |
| BL | 82% (22) | Unknown | Unknown |
HD, Healthy Donor; CDR3, Complementarity-Determining Region 3; RA, Rheumatoid Arthritis; FR3, Frame Work 3; ANCA MPO, Anti-Neutrophil Cytoplasmic Autoantibody (ANCA) Associated Vasculitis (AAV), myeloperoxidase; SLE, Systemic Lupus Erythematosus; pSS, primary Sjogren's Syndrome; SS-A, Anti-Sjögren's-syndrome-related antigen A; SS-B, Anti-Sjögrens's-syndrome-related antigen B; MG, Myasthenia Gravis; MuSK, muscle-specific kinases; IgG4-RD, Immunoglobulin 4 Related Disease; FL, Follicular Lymphoma; CDR2, Complementarity-Determining Region 2; PCFCL, Primary Cutaneous Follicle Center cell Lymphoma; DCBCL, Diffuse large B-cell lymphoma; BL, Burkitt's Lymphoma.